2024
Block admission six monthly return
01 April 2022
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the following information in connection with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.
Name of company:
| Fusion Antibodies plc |
Name of scheme:
| Historic options, EMI and Unapproved Employee Share Option Scheme, as announced on 27 September 2021
|
Period of return:
| From 1 October 2021 to 1 April 2022 |
Number and class of securities not issued under the scheme at the beginning of the period: | 917,083 ordinary shares of 4 pence each in the Company ("Ordinary Shares")
|
Number of securities issued under the scheme during the period:
| 120,000 Ordinary Shares
|
Number of options under the scheme that have lapsed during the period: | Options over 10,000 Ordinary Shares |
Balance under the scheme of securities not yet issued at the end of the period:
| 787,083 Ordinary Shares |
Number and class of securities originally admitted and the date of admission:
| 917,083 Ordinary Shares on 27 September 2021 |
Contact name and telephone number:
| James Fair, CFO via Walbrook PR +44 (0)20 7933 8780
|
Enquiries:
Fusion Antibodies plc | ||
Simon Douglas, Chairman James Fair, Chief Financial Officer | Via Walbrook PR | |
Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke (Sales and Corporate Broking) | ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | |
Anna Dunphy | Mob: +44 (0)7876 741 001 | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
About Fusion Antibodies plc
Fusion is a Belfast-based Collaborative Research Organisation ("CRO") company, listed on AIM, providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
Fusion provides a broad range of services in antibody generation, development, characterisation, optimisation, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client's vision is central to how we work in combining the latest technological advances with cutting edge science. In this work our world-class humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM) to ensure the best molecule goes to the clinic. Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire will address a continuing market need in antibody discovery,
Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $135.4 billion in 2018 and forecast to surpass $300 billion by 2025, a CAGR of 14.26%. As of May 2021, there were 100 approved antibody therapies on the market and more than 570 antibody therapies in clinical development.
2023
Block admission six monthly return
01 April 2022
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the following information in connection with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.
Name of company:
| Fusion Antibodies plc |
Name of scheme:
| Historic options, EMI and Unapproved Employee Share Option Scheme, as announced on 27 September 2021
|
Period of return:
| From 1 October 2021 to 1 April 2022 |
Number and class of securities not issued under the scheme at the beginning of the period: | 917,083 ordinary shares of 4 pence each in the Company ("Ordinary Shares")
|
Number of securities issued under the scheme during the period:
| 120,000 Ordinary Shares
|
Number of options under the scheme that have lapsed during the period: | Options over 10,000 Ordinary Shares |
Balance under the scheme of securities not yet issued at the end of the period:
| 787,083 Ordinary Shares |
Number and class of securities originally admitted and the date of admission:
| 917,083 Ordinary Shares on 27 September 2021 |
Contact name and telephone number:
| James Fair, CFO via Walbrook PR +44 (0)20 7933 8780
|
Enquiries:
Fusion Antibodies plc | ||
Simon Douglas, Chairman James Fair, Chief Financial Officer | Via Walbrook PR | |
Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke (Sales and Corporate Broking) | ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | |
Anna Dunphy | Mob: +44 (0)7876 741 001 | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
About Fusion Antibodies plc
Fusion is a Belfast-based Collaborative Research Organisation ("CRO") company, listed on AIM, providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
Fusion provides a broad range of services in antibody generation, development, characterisation, optimisation, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client's vision is central to how we work in combining the latest technological advances with cutting edge science. In this work our world-class humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM) to ensure the best molecule goes to the clinic. Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire will address a continuing market need in antibody discovery,
Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $135.4 billion in 2018 and forecast to surpass $300 billion by 2025, a CAGR of 14.26%. As of May 2021, there were 100 approved antibody therapies on the market and more than 570 antibody therapies in clinical development.
2022
Block admission six monthly return
01 April 2022
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the following information in connection with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.
Name of company:
| Fusion Antibodies plc |
Name of scheme:
| Historic options, EMI and Unapproved Employee Share Option Scheme, as announced on 27 September 2021
|
Period of return:
| From 1 October 2021 to 1 April 2022 |
Number and class of securities not issued under the scheme at the beginning of the period: | 917,083 ordinary shares of 4 pence each in the Company ("Ordinary Shares")
|
Number of securities issued under the scheme during the period:
| 120,000 Ordinary Shares
|
Number of options under the scheme that have lapsed during the period: | Options over 10,000 Ordinary Shares |
Balance under the scheme of securities not yet issued at the end of the period:
| 787,083 Ordinary Shares |
Number and class of securities originally admitted and the date of admission:
| 917,083 Ordinary Shares on 27 September 2021 |
Contact name and telephone number:
| James Fair, CFO via Walbrook PR +44 (0)20 7933 8780
|
Enquiries:
Fusion Antibodies plc | ||
Simon Douglas, Chairman James Fair, Chief Financial Officer | Via Walbrook PR | |
Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke (Sales and Corporate Broking) | ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | |
Anna Dunphy | Mob: +44 (0)7876 741 001 | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
About Fusion Antibodies plc
Fusion is a Belfast-based Collaborative Research Organisation ("CRO") company, listed on AIM, providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
Fusion provides a broad range of services in antibody generation, development, characterisation, optimisation, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client's vision is central to how we work in combining the latest technological advances with cutting edge science. In this work our world-class humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM) to ensure the best molecule goes to the clinic. Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire will address a continuing market need in antibody discovery,
Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $135.4 billion in 2018 and forecast to surpass $300 billion by 2025, a CAGR of 14.26%. As of May 2021, there were 100 approved antibody therapies on the market and more than 570 antibody therapies in clinical development.
2021
Block admission six monthly return
01 April 2022
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the following information in connection with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.
Name of company:
| Fusion Antibodies plc |
Name of scheme:
| Historic options, EMI and Unapproved Employee Share Option Scheme, as announced on 27 September 2021
|
Period of return:
| From 1 October 2021 to 1 April 2022 |
Number and class of securities not issued under the scheme at the beginning of the period: | 917,083 ordinary shares of 4 pence each in the Company ("Ordinary Shares")
|
Number of securities issued under the scheme during the period:
| 120,000 Ordinary Shares
|
Number of options under the scheme that have lapsed during the period: | Options over 10,000 Ordinary Shares |
Balance under the scheme of securities not yet issued at the end of the period:
| 787,083 Ordinary Shares |
Number and class of securities originally admitted and the date of admission:
| 917,083 Ordinary Shares on 27 September 2021 |
Contact name and telephone number:
| James Fair, CFO via Walbrook PR +44 (0)20 7933 8780
|
Enquiries:
Fusion Antibodies plc | ||
Simon Douglas, Chairman James Fair, Chief Financial Officer | Via Walbrook PR | |
Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke (Sales and Corporate Broking) | ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | |
Anna Dunphy | Mob: +44 (0)7876 741 001 | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
About Fusion Antibodies plc
Fusion is a Belfast-based Collaborative Research Organisation ("CRO") company, listed on AIM, providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
Fusion provides a broad range of services in antibody generation, development, characterisation, optimisation, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client's vision is central to how we work in combining the latest technological advances with cutting edge science. In this work our world-class humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM) to ensure the best molecule goes to the clinic. Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire will address a continuing market need in antibody discovery,
Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $135.4 billion in 2018 and forecast to surpass $300 billion by 2025, a CAGR of 14.26%. As of May 2021, there were 100 approved antibody therapies on the market and more than 570 antibody therapies in clinical development.
2020
Block admission six monthly return
01 April 2022
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the following information in connection with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.
Name of company:
| Fusion Antibodies plc |
Name of scheme:
| Historic options, EMI and Unapproved Employee Share Option Scheme, as announced on 27 September 2021
|
Period of return:
| From 1 October 2021 to 1 April 2022 |
Number and class of securities not issued under the scheme at the beginning of the period: | 917,083 ordinary shares of 4 pence each in the Company ("Ordinary Shares")
|
Number of securities issued under the scheme during the period:
| 120,000 Ordinary Shares
|
Number of options under the scheme that have lapsed during the period: | Options over 10,000 Ordinary Shares |
Balance under the scheme of securities not yet issued at the end of the period:
| 787,083 Ordinary Shares |
Number and class of securities originally admitted and the date of admission:
| 917,083 Ordinary Shares on 27 September 2021 |
Contact name and telephone number:
| James Fair, CFO via Walbrook PR +44 (0)20 7933 8780
|
Enquiries:
Fusion Antibodies plc | ||
Simon Douglas, Chairman James Fair, Chief Financial Officer | Via Walbrook PR | |
Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke (Sales and Corporate Broking) | ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | |
Anna Dunphy | Mob: +44 (0)7876 741 001 | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
About Fusion Antibodies plc
Fusion is a Belfast-based Collaborative Research Organisation ("CRO") company, listed on AIM, providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
Fusion provides a broad range of services in antibody generation, development, characterisation, optimisation, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client's vision is central to how we work in combining the latest technological advances with cutting edge science. In this work our world-class humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM) to ensure the best molecule goes to the clinic. Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire will address a continuing market need in antibody discovery,
Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $135.4 billion in 2018 and forecast to surpass $300 billion by 2025, a CAGR of 14.26%. As of May 2021, there were 100 approved antibody therapies on the market and more than 570 antibody therapies in clinical development.
2019
Block admission six monthly return
01 April 2022
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the following information in connection with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.
Name of company:
| Fusion Antibodies plc |
Name of scheme:
| Historic options, EMI and Unapproved Employee Share Option Scheme, as announced on 27 September 2021
|
Period of return:
| From 1 October 2021 to 1 April 2022 |
Number and class of securities not issued under the scheme at the beginning of the period: | 917,083 ordinary shares of 4 pence each in the Company ("Ordinary Shares")
|
Number of securities issued under the scheme during the period:
| 120,000 Ordinary Shares
|
Number of options under the scheme that have lapsed during the period: | Options over 10,000 Ordinary Shares |
Balance under the scheme of securities not yet issued at the end of the period:
| 787,083 Ordinary Shares |
Number and class of securities originally admitted and the date of admission:
| 917,083 Ordinary Shares on 27 September 2021 |
Contact name and telephone number:
| James Fair, CFO via Walbrook PR +44 (0)20 7933 8780
|
Enquiries:
Fusion Antibodies plc | ||
Simon Douglas, Chairman James Fair, Chief Financial Officer | Via Walbrook PR | |
Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke (Sales and Corporate Broking) | ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | |
Anna Dunphy | Mob: +44 (0)7876 741 001 | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
About Fusion Antibodies plc
Fusion is a Belfast-based Collaborative Research Organisation ("CRO") company, listed on AIM, providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
Fusion provides a broad range of services in antibody generation, development, characterisation, optimisation, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client's vision is central to how we work in combining the latest technological advances with cutting edge science. In this work our world-class humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM) to ensure the best molecule goes to the clinic. Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire will address a continuing market need in antibody discovery,
Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $135.4 billion in 2018 and forecast to surpass $300 billion by 2025, a CAGR of 14.26%. As of May 2021, there were 100 approved antibody therapies on the market and more than 570 antibody therapies in clinical development.
2018
Block admission six monthly return
01 April 2022
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the following information in connection with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.
Name of company:
| Fusion Antibodies plc |
Name of scheme:
| Historic options, EMI and Unapproved Employee Share Option Scheme, as announced on 27 September 2021
|
Period of return:
| From 1 October 2021 to 1 April 2022 |
Number and class of securities not issued under the scheme at the beginning of the period: | 917,083 ordinary shares of 4 pence each in the Company ("Ordinary Shares")
|
Number of securities issued under the scheme during the period:
| 120,000 Ordinary Shares
|
Number of options under the scheme that have lapsed during the period: | Options over 10,000 Ordinary Shares |
Balance under the scheme of securities not yet issued at the end of the period:
| 787,083 Ordinary Shares |
Number and class of securities originally admitted and the date of admission:
| 917,083 Ordinary Shares on 27 September 2021 |
Contact name and telephone number:
| James Fair, CFO via Walbrook PR +44 (0)20 7933 8780
|
Enquiries:
Fusion Antibodies plc | ||
Simon Douglas, Chairman James Fair, Chief Financial Officer | Via Walbrook PR | |
Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke (Sales and Corporate Broking) | ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | |
Anna Dunphy | Mob: +44 (0)7876 741 001 | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
About Fusion Antibodies plc
Fusion is a Belfast-based Collaborative Research Organisation ("CRO") company, listed on AIM, providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
Fusion provides a broad range of services in antibody generation, development, characterisation, optimisation, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client's vision is central to how we work in combining the latest technological advances with cutting edge science. In this work our world-class humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM) to ensure the best molecule goes to the clinic. Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire will address a continuing market need in antibody discovery,
Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $135.4 billion in 2018 and forecast to surpass $300 billion by 2025, a CAGR of 14.26%. As of May 2021, there were 100 approved antibody therapies on the market and more than 570 antibody therapies in clinical development.
2017
Block admission six monthly return
01 April 2022
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the following information in connection with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.
Name of company:
| Fusion Antibodies plc |
Name of scheme:
| Historic options, EMI and Unapproved Employee Share Option Scheme, as announced on 27 September 2021
|
Period of return:
| From 1 October 2021 to 1 April 2022 |
Number and class of securities not issued under the scheme at the beginning of the period: | 917,083 ordinary shares of 4 pence each in the Company ("Ordinary Shares")
|
Number of securities issued under the scheme during the period:
| 120,000 Ordinary Shares
|
Number of options under the scheme that have lapsed during the period: | Options over 10,000 Ordinary Shares |
Balance under the scheme of securities not yet issued at the end of the period:
| 787,083 Ordinary Shares |
Number and class of securities originally admitted and the date of admission:
| 917,083 Ordinary Shares on 27 September 2021 |
Contact name and telephone number:
| James Fair, CFO via Walbrook PR +44 (0)20 7933 8780
|
Enquiries:
Fusion Antibodies plc | ||
Simon Douglas, Chairman James Fair, Chief Financial Officer | Via Walbrook PR | |
Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke (Sales and Corporate Broking) | ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | |
Anna Dunphy | Mob: +44 (0)7876 741 001 | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
About Fusion Antibodies plc
Fusion is a Belfast-based Collaborative Research Organisation ("CRO") company, listed on AIM, providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
Fusion provides a broad range of services in antibody generation, development, characterisation, optimisation, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client's vision is central to how we work in combining the latest technological advances with cutting edge science. In this work our world-class humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM) to ensure the best molecule goes to the clinic. Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire will address a continuing market need in antibody discovery,
Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $135.4 billion in 2018 and forecast to surpass $300 billion by 2025, a CAGR of 14.26%. As of May 2021, there were 100 approved antibody therapies on the market and more than 570 antibody therapies in clinical development.
